EXCEDE® approved for metritis treatment in just two doses
Source: Pfizer Animal Health
Pfizer Animal Health announces that EXCEDE® (ceftiofur crystalline free acid) Sterile Suspension is now approved by the Food and Drug Administration (FDA) for the treatment of acute postpartum metritis in just two doses. EXCEDE continues to be backed by the Residue Free Guarantee™.*
“The two-dose regimen of EXCEDE is an efficacious and cost-effective metritis treatment option with zero milk discard,” says Doug Hammon, DVM, Ph.D., senior manager, Cattle Technical Services, Pfizer Animal Health. “I believe veterinarians and producers will find the two-dose regimen for EXCEDE to be a more convenient alternative to daily metritis treatments.”
Treatment of metritis with EXCEDE consists of two doses, administered 72 hours apart at the base of opposite ears. For example, the first dose can be administered at the base of the left ear on a Friday and the second at the base of the right ear 72 hours later on the following Monday. It is the advanced, sustained-release formulation of EXCEDE that provides extended disease therapy in each dose, eliminating the need for the daily treatments typical of other metritis therapy. This can help improve protocol compliance and reduce the chances of a treatment relapse.
In multiple studies, this protocol has been demonstrated to be effective in treating acute metritis (0 to 10 days postpartum) associated with bacterial organisms susceptible to ceftiofur in lactating dairy cattle. Field research,1 conducted on 15 large dairies across the country, found that 74.3 percent of cows with acute metritis were cured after being treated with two doses of EXCEDE. This compares with only 55.3 percent of the untreated control group.
In addition to the proven performance and safety of ceftiofur against metritis, EXCEDE is backed by the Residue Free Guarantee* and offers the residue risk assurance of zero milk discard and a known meat withdrawal time of 13 days after the last dose given.
“Pfizer Animal Health continues to invest in expanding or adding label claims to allow veterinarians and producers the continued on label use of our products,” Hammon says. “Scrutiny of drug residues is intensifying, making it more important than ever for producers to work with their veterinarian to ensure their metritis treatment reduces their risk of a residue violation.”
More information and a video explaining use can be found here.
